first issued 18 August 2022
Overview
The aim of this guide is to support national immunization programme managers and others responsible for implementing human rabies vaccine programmes to:
inform policy discussions and operational planning for introducing or expanding ra...bies post-exposure prophylaxis (PEP) into a national immunization programme (e.g. through the national immunization programme, or other programmes); and
highlight considerations specific to rabies PEP for integration into existing systems, including for implementation, and monitoring and evaluation.
While the guide is mainly intended for programme managers and focuses on human vaccination, complementary animal health measures are highlighted where relevant given the zoonotic nature of rabies.
The guide was developed collaboratively with input from technical experts in rabies and immunization, vaccines and biologicals.
more
Rabies is fatal, vaccine-preventable disease responsible for an estimated 59,000 human deaths each year. Most cases are transmitted by dogs, and most deaths occur in underserved populations in Africa and Asia. Approximately 40% of deaths occur in ch...ildren.
more
Efforts driving universal coverage have recently been strengthened through implementation of the Global Vaccine Action Plan (GVAP) where cost estimates for immunization support were developed totaling US$40 billion of donor assistance by 2020. In ad...dition to resource mobilization, there has been an increasing focus on improving both vaccine access and delivery systems. We track donor assistance for immunization by funding objective and channel from 1990 to 2016, and illustrate projections through 2020 to inform progress of the GVAP.
more
Protection from a Single Dose of HPV Vaccine A major public health impact from IARC studies of vaccine efficacy.
The Virtual cGMP Training Marathon for Vaccine Manufacturing: Principles into Practice took place from 12 Sep to 10 Oct 2023 to continue to provide manufacturers & regulators with a comprehensive array of topics to build understanding of current WHO... & international GMP standards, technological advancements, industry practices and regulatory expectations specific to the vaccine manufacturing context. Some of the topics include computer system validation, data integrity, challenges in lyophilization and others. Real world examples and case studies will be used to show how to interpret current and recently new good manufacturing practices requirements from a practical point of view and to implement appropriate approaches.
more
Qu’est-ce qu’un vaccin? Comment fonctionnent les vaccins ARNm contre la COVID-19 et quelle est leur importance? Regardez cette vidéo pour tout savoir sur les ... medbox">vaccins ARNm sûrs et efficaces contre la COViD-19
more
The safety of medicines in Zambia - why health workers need to take action | Produced by the National Pharmacovigilance Unit (NPVU)
An example of integration of research into epidemic response.
This article was published on December 10, 2020, and updated on December 16, 2020, at NEJM.org. DOI: 10.1056/NEJMoa2034577
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary include...d in the background document referenced below.
first issued 8 January 2021, updated 15 June 2021, updated 19 November 2021, updated 21 January 2022, updated 18 August 2022. Available in other languages https://apps.who.int/iris/handle/10665/361720
more
Interim Guidance, published 11 January 2021.
The cold chain is necessary to prevent damage to vaccines caused by heat exposure. However, improper use of cold chain equipment may cause damage to freeze-sensitive ...edbox">vaccines (i.e. those vaccines containing alum adjuvant or oil-emulsion adjuvant). Studies conducted in several countries with hot and cold climates show frequent occurrences of sub-zero temperatures in the cold chain. The most common cause of exposure to freezing temperature is the failure to correctly condition ice packs prior to transport. Vaccines that are inadvertently frozen lose potency, increase wastage rates and increase the risk of adverse events following immunization (AEFI). Vaccine carriers protect vaccine potency during immunization sessions and transport to outreach sites. This guidance document is intended to help inform which type of vaccine carrier to select based on local context, to maintain vaccine quality, especially at service delivery points.
more
nterim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022, updated 18 August 2022
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence s...ummary included in the background document referenced below.
This document has been updated: Version 15 March 2022.
more